BioPorto A/S

Equities

BIOPOR

DK0011048619

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Copenhagen Other stock markets 10:45:53 2024-04-26 am EDT			5-day change	1st Jan Change
1.24 ^DKK	+0.49%		-1.43%	-40.67%

Apr. 10	BioPorto Names New Chief Legal Officer	MT
Apr. 10	Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024	CI

BioPorto A/S Provides Revenue Guidance for the Full Year 2024

February 22, 2024 at 01:32 am EST

BioPorto A/S provided earnings guidance for the full year 2024. In 2024, the company is targeting to achieve total revenue of DKK 40 million (USD 6 million) which would correspond to a growth rate of 30% compared to 2023. Growth will be driven by increased sales of NGAL products ?

primarily in the US following the FDA clearance supplemented by growth in the rest of the world. Revenue is expected to be back-end loaded, as US clinical commercialization of ProNephro AKI (NGAL) will commence in the second half of 2024.

Latest news about BioPorto A/S

BioPorto Names New Chief Legal Officer	Apr. 10	MT
Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024	Apr. 10	CI
Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election	Apr. 05	CI
BioPorto A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 04	CI
BioPorto Makes Interim CEO Permanent	Apr. 02	MT
BioPorto A/S Appoints Peter Mørch Eriksen as Permanent Group CEO	Apr. 02	CI
Bioporto A/S Announces Peter Mørch Eriksen Will Not Stand for Re-Election to the Board of Directors	Apr. 02	CI
Transcript : BioPorto A/S - Special Call	Feb. 22
BioPorto A/S Provides Revenue Guidance for the Full Year 2024	Feb. 22	CI
Roche: extended collaboration with Denmark's BioPorto	Feb. 20	CF
BioPorto Expands Global Distribution Partnership with Roche Diagnostics	Feb. 20	MT
Roche Diagnostics and BioPorto A/S Expand Collaboration	Feb. 20	CI
BioPorto CEO Steps Down; Interim Successor Appointed	Jan. 10	MT
BioPorto A/S Announces CEO Changes	Jan. 09	CI
Transcript : BioPorto A/S - Special Call	Dec. 10
BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United States	Dec. 07	CI
BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member	Dec. 04	CI
Transcript : BioPorto A/S, Q3 2023 Earnings Call, Nov 01, 2023	Nov. 01
Transcript : BioPorto A/S, Q3 2023 Earnings Call, Nov 01, 2023	Nov. 01
BioPorto A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 01	CI
Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023	23-10-31	CI
BioPorto CFO Steps Down; Search for Successor Underway	23-09-19	MT
Bioporto A/S Announces Resignation of Neil Goldman as CFO	23-09-19	CI
Transcript : BioPorto A/S, Q2 2023 Earnings Call, Aug 01, 2023	23-08-01
BioPorto A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-01	CI

Chart BioPorto A/S

Duration

Period

More charts

Company Profile

Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Companyâs portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-04-30 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.24 DKK

Average target price

5 DKK

Spread / Average Target

+303.23%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
BIOPORTO A/S	-40.67%	67.41M
BIOMÉRIEUX	+0.89%	12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-10.29%	7.61B
DIASORIN S.P.A.	+1.78%	5.41B
AUTOBIO DIAGNOSTICS CO., LTD.	-1.16%	4.51B
LANTHEUS HOLDINGS, INC.	+5.74%	4.49B
10X GENOMICS, INC.	-50.70%	3.29B
ANDON HEALTH CO., LTD.	+12.21%	2.73B
VITROLIFE AB	-16.13%	2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-11.50%	1.73B

Diagnostic & Testing Substances